US-based Trifecta Health and Trifecta Med Spa announced on Tuesday that they have entered two strategic cooperation agreements with United States-based healthcare company Eli Lilly and United States-based NovoCare Pharmacy, aimed at improving patient access to high-quality obesity treatments.

Trifecta Health and Trifecta Med Spa are collaborating with Eli Lilly to provide patients with access to Zepbound (tirzepatide) single-dose vials. This collaboration with the LillyDirect self-pay pharmacy channel is intended to enable clinically qualified patients to receive the FDA-approved medication delivered directly to them at the self-pay price.

Also, Trifecta Health and Trifecta Med Spa are collaborating with NovoCare Pharmacy to provide seamless access to Wegovy at the lowest cash price available. This collaboration allows patients to receive the FDA-approved GLP-1 medication directly from Novo Nordisk without ever leaving the Trifecta Health and Trifecta Med Spa website.